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Summary
Background Anthracyclines and taxanes have been the standard neoadjuvant chemotherapies for breast cancer in the 
past decade. We aimed to assess safety and eﬃ  cacy of the addition of gemcitabine to accelerated paclitaxel with 
epirubicin and cyclophosphamide, and also the eﬀ ect of sequencing the blocks of epirubicin and cyclophosphamide 
and paclitaxel (with or without gemcitabine).
Methods In our randomised, open-label, 2×2 factorial phase 3 trial (Neo-tAnGo), we enrolled women (aged >18 years) 
with newly diagnosed breast cancer (tumour size >20 mm) at 57 centres in the UK. Patients were randomly assigned 
via a central randomisation procedure to epirubicin and cyclophosphamide then paclitaxel (with or without 
gemcitabine) or paclitaxel (with or without gemcitabine) then epirubicin and cyclophosphamide. Four cycles of each 
component were given. The primary endpoint was pathological complete response (pCR), deﬁ ned as absence of 
invasive cancer in the breast and axillary lymph nodes. This study is registered with EudraCT (2004-002356-34), 
ISRCTN (78234870), and ClinicalTrials.gov (NCT00070278).
Findings Between Jan 18, 2005, and Sept 28, 2007, we randomly allocated 831 participants; 207 received epirubicin and 
cyclophosphamide then paclitaxel; 208 were given paclitaxel then epirubicin and cyclophosphamide; 208 had 
epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine; and 208 received paclitaxel and gemcitabine 
then epirubicin and cyclophosphamide. 828 patients were eligible for analysis. Median follow-up was 47 months 
(IQR 37–51). 207 (25%) patients had inﬂ ammatory or locally advanced disease, 169 (20%) patients had tumours larger 
than 50 mm, 413 (50%) patients had clinical involvement of axillary nodes, 276 (33%) patients had oestrogen receptor 
(ER)-negative disease, and 191 (27%) patients had HER2-positive disease. Addition of gemcitabine did not increase 
pCR: 70 (17%, 95% CI 14–21) of 404 patients in the epirubicin and cyclophosphamide then paclitaxel group achieved 
pCR compared with 71 (17%, 14–21) of 408 patients who received additional gemcitabine (p=0·98). Receipt of a taxane 
before anthracycline was associated with improved pCR: 82 (20%, 95% CI 16–24) of 406 patients who received 
paclitaxel with or without gemcitabine followed by epirubicin and cyclophosphamide achieved pCR compared with 
59 (15%, 11–18) of 406 patients who received epirubicin and cyclophosphamide ﬁ rst (p=0·03). Grade 3 toxicities were 
reported at expected levels: 173 (21%) of 812 patients who received treatment and had full treatment details had 
grade 3 neutropenia, 66 (8%) had infection, 41 (5%) had fatigue, 41 (5%) had muscle and joint pains, 37 (5%) had 
nausea, 36 (4%) had vomiting, 34 (4%) had neuropathy, 23 (3%) had transaminitis, 16 (2%) had acute hypersensitivity, 
and 20 (2%) had a rash. 86 (11%) patients had grade 4 neutropenia and 3 (<1%) had grade 4 infection.
Interpretation Although addition of gemcitabine to paclitaxel and epirubicin and cyclophosphamide chemotherapy 
does not improve pCR, sequencing chemotherapy so that taxanes are received before anthracyclines could improve 
pCR in standard neoadjuvant chemotherapy for breast cancer.
Funding Cancer Research UK, Eli Lilly, Bristol-Myers Squibb.
Introduction
Survival of patients with early breast cancer has improved 
substantially in the past 20 years.1 However, incidence of 
breast cancer has increased and continues to be a major 
health problem. The Early Breast Cancer Trialists 
Collaborative Group overview analyses,2,3 and individual 
trial data have shown beneﬁ t for adjuvant anthracyclines4–6 
and taxane-containing chemotherapy.7–9
Progress made through large adjuvant randomised 
treatment trials has been relatively slow. Follow-up is 
necessarily prolonged to meet the prespeciﬁ ed event-
rate criteria for disease-free survival (DFS) and overall 
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survival analyses, as deﬁ ned in statistical analysis 
plans.10 However, in the neoadjuvant setting trials can 
report the primary endpoint of pathological complete 
response (pCR) more rapidly than their adjuvant 
counterparts. Broad acceptance of the long-term validity 
of neoadjuvant trials awaits formal comparison with 
data acquired from parallel, conventional adjuvant 
studies. tAnGo11 and Neo-tAnGo were designed to 
provide this cross reference, because both trials 
investigated the addition of gemcitabine to standard 
chemotherapy, although the sequence of chemotherapy 
was not addressed in tAnGo.
Neo-tAnGo was a randomised phase 3 neoadjuvant trial 
that aimed to assess beneﬁ ts of addition of gemcitabine to 
accelerated paclitaxel with epirubicin and cyclophospha-
mide, and also the eﬀ ect of sequencing of epirubicin and 
cyclophosphamide, and paclitaxel (with and without 
gemcitabine) blocks. Gemcitabine is an eﬀ ective drug in 
metastatic disease12,13 and other neoadjuvant or adjuvant 
trials have addressed similar questions for antimetabolites, 
with gemcitabine14,15 or oral capecitabine.16 Neo-tAnGo 
was designed and started before the introduction of 
adjuvant trastuzumab for HER2-positive disease.
Methods
Study design and participants
In the Neo-tAnGo phase 3 randomised trial, we used a 
2 × 2 factorial design to address both the role of 
gemcitabine in a sequential neoadjuvant chemotherapy 
regimen of epirubicin and cyclophosphamide and 
paclitaxel, and also the sequence of administration of 
these treatment components, in terms of short-term and 
long-term outcomes in women presenting with early 
breast cancer.
We enrolled women aged older than 18 years with a 
histological diagnosis of early invasive breast cancer, 
with a radiological tumour size of more than 20 mm 
with or without axillary involvement. Women were 
enrolled at 57 sites (NCRN Cancer Centres and Cancer 
Units) in the UK. Women with inﬂ ammatory cancer, 
T4 tumours with direct extension to the chest wall or 
skin, and ipsilateral supraclavicular lymph-node 
involvement were eligible with any size of primary 
tumour. We regarded hormone receptor status 
(oestrogen [ER] and progesterone [PR]) as positive when 
Allred score was 3 or higher. HER2 status was regarded 
as positive when immunohistochemistry was 3+, or 2+ 
with evidence of ampliﬁ cation of the HER2 gene on 
ﬂ uorescence in-situ hybridisation. Other eligibility 
criteria were adequate cardiac function, no myocardial 
infarction during the previous 6 months, adequate bone 
marrow, hepatic, and renal function, and appropriate 
ECOG performance status (0–2). No previous exposure 
to chemotherapy, radiotherapy or endocrine therapy was 
allowed. Full eligibility criteria can be found in the trial 
protocol and in the appendix. Patients provided written 
informed consent.
Neo-tAnGo was an investigator designed and led trial, 
which was granted Clinical Trials Authorisation from 
the Medicines and Healthcare products Regulatory 
Agency (MHRA) on June 17, 2004, and approved by the 
multicentre research ethics committee nationally on 
Nov 1, 2004, and subsequently the local research ethics 
committees at all participating centres. The study was 
undertaken by the UK National Cancer Research 
Institute (NCRI).
Randomisation and masking
In our open-label trial, eligible participants were randomly 
allocated 1:1:1:1 to receive epirubicin and cyclophosphamide 
followed by paclitaxel, paclitaxel followed by epirubicin 
and cyclophosphamide, epirubicin and cyclophosphamide 
followed by paclitaxel and gemcitabine, or paclitaxel and 
gemcitabine followed by epirubicin and cyclophosphamide. 
The paclitaxel (with or without gemcitabine) was 
accelerated. Stratiﬁ cation by minimisation was under-
taken by age (≤50 years and >50 years), ER status (positive 
and negative), primary tumour size (≤5 cm and >5 cm), 
clinical involvement of axillary nodes, and inﬂ ammatory 
or locally advanced disease. We intended chemotherapy to 
start within 4 weeks of randomisation. Chemotherapy 
regimens used were epirubicin 90 mg/m² and 
cyclophosphamide 600 mg/m² once every 21 days, and 
paclitaxel 175 mg/m² with or without gemcitabine 
2000 mg/m² once every 14 days. Each treatment 
component was given for four cycles per patient. 
Treatment allocations were made by telephoning the 
Cancer Research UK Trials Unit (Birmingham, UK), who 
used their central computerised minimisation procedure 
to generate the patients’ random allocation.
Procedures
Our primary endpoint was pCR, deﬁ ned as absence of 
invasive breast cancer in the breast and axillary lymph 
nodes, after neoadjuvant chemotherapy. A two-reader 
review of pathology reports was undertaken, masked to 
treatment group, by the chief investigator (HME) and the 
study pathologist (EP), for patients who had surgery. 
A detailed analysis of this review process has been 
published elsewhere.17 Residual non-invasive ductal 
carcinoma in situ was allowed.
Secondary endpoints reported here include DFS and 
overall survival. We assessed adverse events for each 
chemotherapy cycle according to Common Terminology 
Criteria for Adverse Events (CTCAE) grade. We also 
recorded use of growth factor support (usually granulocyte 
colony stimulating factor [GCSF]).
The maximum permitted dose delay or interruption 
was 4 weeks to allow recovery from severe toxicity or for 
unscheduled procedures (eg, emergency surgery).
If neutropenic fever or sepsis occurred after a cycle of 
chemotherapy, the next cycle was delayed until the 
absolute neutrophil count was at least 1·0 × 10⁹ cells per L. 
Following a delay, either dose reduction of all drugs to 
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80%, or GCSF support with 100% dose were allowed, and 
all remaining cycles of the same four-cycle block were 
given at those doses. For persistent thrombocytopenia, 
the next cycle was delayed until patients had at least 
100 × 10⁹ platelets per L and was reduced to 80%, 
maintaining this dose reduction for subsequent cycles. 
Depending on sequence allocation, cycles from the next 
block of treatment were commenced at full protocol dose, 
and permitted delays and reductions were made as 
necessary. Primary prophylaxis with GCSF was not 
provided with either epirubicin and cyclophosphamide or 
accelerated paclitaxel (with or without gemcitabine). Once 
started, prophylactic GCSF was usually continued into 
the second phase of chemotherapy at the discretion of the 
responsible physician.
If grade 2 neuropathy occurred during treatment with 
paclitaxel, remaining doses were reduced to 135 mg/m² 
(gemcitabine was unchanged). If grade 3 neuropathy 
occurred, paclitaxel and gemcitabine were stopped. If 
fewer than four cycles of paclitaxel (with or without 
gemcitabine) had been given, additional epirubicin and 
cyclophosphamide cycles were allowed up to a maximum 
11 did not undergo surgery
 7 had early disease recurrence (2 on paclitaxel followed by EC, 4 on EC followed by gemcitabine-paclitaxel, 1 on gemcitabine-paclitaxel followed by EC)
 2 protocol violators refused surgery (EC followed by paclitaxel) 
 2 died before surgery (1 in the EC followed by paclitaxel group from deep vein thrombosis and pulmonary embolism, 1 in the paclitaxel followed by EC group from neutropenic sepsis and pneumonia) 
 5 had unobtainable pathology reports from surgery (1 in the EC followed by paclitaxel group, 2 in the paclitaxel followed by EC, 2 in the paclitaxel and gemcitabine followed by EC group)
Analysis of the role of gemcitabine
413 in the EC and paclitaxel group vs 415 in the EC and gemcitabine-paclitaxel group
Analysis of the role of sequencing
414  in the EC followed by paclitaxel (with or without gemcitabine) group vs 414 in the paclitaxel
 (with or without gemcitabine) followed by EC group 
Analysis of the role of gemcitabine 
404 in the EC and paclitaxel group vs 408 in the EC and gemcitabine-paclitaxel group
Analysis of the role of sequencing
406 in the EC followed by paclitaxel (with or without gemcitabine) group vs 406 in the
paclitaxel (with or without gemcitabine) followed by EC group
 
1 ineligible (excluded from analyses)
 1 misreported ultrasound size of 
 14·8 cm amended to 14·8 mm
2 ineligible (excluded from analyses)
 1 clinically reported 32 mm tumour, 
  but only 15 mm on ultrasound
 1 had received brachytherapy for
  cervical cancer 32 years previously
6 protocol violators (included in analyses)
 1 opted oﬀ study before treatment 
 3 stopped chemotherapy early and 
  proceeded to surgery 
 2 received non-study drugs after allergic 
  reactions to paclitaxel and switched to 
  ﬂuorouracil, epirubicin, and
  cyclophosphamide 
5 protocol violators (included in analyses)
 1 opted oﬀ study before treatment
 3 stopped chemotherapy early and  
  proceeded to surgery
 1 received wrong drug or missed out 
  drugs in error   
10 protocol violators (included in analyses)
 2 opted oﬀ study before treatment 
 5 stopped chemotherapy early and 
  proceeded to surgery 
 2 received non-study drugs after allergic 
  reactions to paclitaxel and switched to 
  ﬂuorouracil, epirubicin, and
  cyclophosphamide 
 1 received non-study drugs after allergic 
  reactions to paclitaxel and switched to
  docetaxel 
6 protocol violators (included in analyses)
 2 stopped chemotherapy early and
  proceeded to surgery 
 2 refused surgery
 2 received wrong drug or missed out 
  drugs in error
831 participants randomly allocated
828 included in treatment comparisons
812 included in the primary endpoint analysis
208 assigned to gemcitabine-paclitaxel
 followed by EC
208 assigned to EC followed by
 gemcitabine-paclitaxel
208 assigned to paclitaxel followed by EC207 assigned to EC followed by paclitaxel
Figure 1: Trial proﬁ le
EC=epirubicin and cyclophosphamide.
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Component analysis Sequencing analysis Overall (n=828)
EC and paclitaxel
(n=413)
EC and paclitaxel-gemcitabine 
(n=415)
EC followed by paclitaxel 
with or without gemcitabine 
(n=414)
Paclitaxel with or without 
gemcitabine followed by EC 
(n=414)
Demographics
Age, years*
≤50 261 (63%) 261 (63%) 260 (63%) 262 (63%) 522 (63%)
>50 152 (37%) 154 (37%) 154 (37%) 152 (37%) 306 (37%)
ER status*†
Negative 137 (33%) 139 (33%) 139 (34%) 137 (33%) 276 (33%)
Positive 276 (67%) 276 (67%) 275 (66%) 277 (67%) 552 (67%)
PR status† (75% known)
Negative 154 (49%) 152 (49%) 144 (47%) 162 (51%) 306 (49%)
Positive 158 (51%) 158 (51%) 160 (53%) 156 (49%) 316 (51%)
HER2 status‡ (85% known)
Negative 257 (73%) 256 (73%) 251 (72%) 262 (74%) 513 (73%)
Positive 94 (27%) 97 (27%) 97 (28%) 94 (26%) 191 (27%)
Tumour size*
≤50 mm 330 (80%) 329 (79%) 332 (80%) 327 (79%) 659 (80%)
>50 mm 83 (20%) 86 (21%) 82 (20%) 87 (21%) 169 (20%)
Clinical involvement of axillary nodes*
No 208 (50%) 207 (50%) 208 (50%) 207 (50%) 415 (50%)
Yes 205 (50%) 208 (50%) 206 (50%) 207 (50%) 413 (50%)
Inﬂ ammatory or locally advanced disease*
No 309 (75%) 312 (75%) 309 (75%) 312 (75%) 621 (75%)
Yes§ 104 (25%) 103 (25%) 105 (25%) 102 (25%) 207 (25%)
Inﬂ ammatory disease 47 (45%) 55 (53%) 55 (52%) 47 (46%) 102 (49%)
Advanced disease 76 (73%) 69 (67%) 71 (68%) 74 (73%) 145 (70%)
Menopausal status
Premenopausal 235 (57%) 235 (57%) 235 (57%) 235 (57%) 470 (57%)
Perimenopausal 26 (6%) 19 (5%) 22 (5%) 23 (6%) 45 (5%)
Postmenopausal 107 (26%) 114 (27%) 114 (28%) 107 (26%) 221 (27%)
Bilateral oophorectomy 4 (1%) 0 (0%) 1 (<1%) 3 (1%) 4 (<1%)
Hysterectomy 15 (4%) 23 (6%) 18 (4%) 20 (5%) 38 (5%)
Not known 26 (6%) 24 (6%) 24 (6%) 26 (6%) 50 (6%)
Number of invasive tumours
1 236 (57%) 236 (57%) 243 (59%) 229 (55%) 472 (57%)
≥2 172 (42%) 176 (42%) 165 (40%) 183 (44%) 348 (42%)
Not known 5 (1%) 3 (1%) 6 (1%) 2 (1%) 8 (1%)
Details of largest breast tumour
Tumour type¶
Ductal or no special type 325 (79%) 325 (78%) 315 (76%) 335 (81%) 650 (79%)
Lobular 35 (8%) 41 (10%) 38 (9%) 38 (9%) 76 (9%)
Tubular or cribform 6 (1%) 4 (1%) 6 (1%) 4 (1%) 10 (1%)
Mucinous 2 (<1%) 4 (1%) 3 (1%) 3 (1%) 6 (1%)
Medullary 1 (<1%) 2 (<1%) 1 (<1%) 2 (<1%) 3 (1%)
Other 20 (5%) 18 (4%) 24 (6%) 14 (3%) 38 (5%)
Not known 40 (10%) 46 (11%) 43 (10%) 43 (10%) 86 (10%)
Tumour grade
1 (well diﬀ erentiated) 13 (3%) 8 (2%) 11 (3%) 10 (2%) 21 (3%)
2 (moderately diﬀ erentiated) 123 (30%) 122 (29%) 130 (31%) 115 (28%) 245 (30%)
3 (poorly diﬀ erentiated) 158 (38%) 172 (41%) 159 (38%) 171 (41%) 330 (40%)
Not known 119 (29%) 113 (27%) 114 (28%) 118 (29%) 232 (28%)
(Continues on next page)
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of six cycles in total, at the discretion of the treating 
consultant.
Gemcitabine was reduced to 80% in the event 
of grade 3 hepatic toxicity (transaminitis; aspartate amino-
 transferase or alanine aminotransferase ≥5–20 × upper 
limit of normal [ULN]) on day of treatment, at clinician’s 
discretion because transaminitis is not known to aﬀ ect 
gemcitabine clearance. We were unable to substantiate 
earlier concerns about gemcitabine’s potential for 
clinically signiﬁ cant hepatic impairment.
Cardiac toxicity was not anticipated at the cumulative 
doses of epirubicin of 360 mg/m². However, if 
congestive cardiac failure developed, patients were 
investigated and treated as appropriate, epirubicin was 
discontinued, and other chemotherapy was given at the 
discretion of the treating clinician.
In the event of gemcitabine-related pulmonary toxicity 
of CTCAE grade 2 or worse, the patient was discontinued 
from study therapy.
Paclitaxel infusion was stopped if mild symptoms of 
skin rash, ﬂ ushing, and localised pruritus occurred. 
Intravenous steroids and antihistamines were given and 
immediate slow rechallenge of chemotherapy was used 
on recovery. Also, paclitaxel infusion was stopped if 
moderate symptoms of generalised pruritus or rash, mild 
dyspnoea, or mild hypotension occurred and intravenous 
steroids and antihistamines were given. 48 h of steroids 
were then advised before cautious paclitaxel rechallenge. 
If severe symptoms occurred, including bronchospasm, 
generalised urticaria, angio-oedema, hypotension 
(systolic blood pressure <100 mm Hg), or life-threatening 
anaphylaxis, paclitaxel infusion was stopped and 
treatment was given with intramuscular  epinephrine 
1 mL 1:1000, intravenous steroids, and intravenous 
antihistamines; rechallenge was contraindicated.
Surgery (breast and axillary), radiotherapy, and 
adjuvant endocrine treatment were given according to 
local protocols. Patients with HER2-positive disease did 
not receive neoadjuvant trastuzumab, but received 
adjuvant trastuzumab according to local protocols. 
Clinical surveillance was continued for 5 years at the 
clinical centres, and after 5 years from the Oﬃ  ce for 
National Statistics (ONS). Patients will continue to 
receive follow-up through the National Cancer 
Intelligence Network (NCIN) who will monitor for DFS 
and overall survival.
Statistical analysis
Our power calculations assumed that the pCR would 
be  20% after standard treatment (epirubicin and 
cyclophosphamide followed by paclitaxel). On this basis, 
we aimed to randomly allocate 200 patients into each of 
the four treatment groups, yielding combined data for 
400 patients into each group for the two questions (ie, 
eﬃ  cacy and safety of the addition of gemcitabine to 
paclitaxel plus epirubicin and cyclophosphamide treat-
ment [component analysis] and order of chemo therapy 
regimens [sequencing analysis]).  This would allow an 
absolute diﬀ erence in the pCR in excess  of 10% to be 
detected at the 5% (two-sided) level of signiﬁ cance with 
85% power. Statistical analysis  was undertaken on an 
intention-to-treat basis  and all protocol violators were 
analysed within their randomised groups. All reported 
p values are two-sided.
Component analysis Sequencing analysis Overall (n=828)
EC and paclitaxel
(n=413)
EC and paclitaxel-gemcitabine 
(n=415)
EC followed by paclitaxel 
with or without gemcitabine 
(n=414)
Paclitaxel with or without 
gemcitabine followed by EC 
(n=414)
(Continued from previous page)
Clinical characteristics¶
Nipple retraction 40 (10%) 44 (11%) 35 (8%) 49 (12%) 84 (10%)
Skin inﬁ ltration 15 (4%) 16 (4%) 17 (4%) 14 (3%) 31 (4%)
Peau d’orange 26 (6%) 31 (7%) 30 (7%) 27 (7%) 57 (7%)
Redness 28 (7%) 27 (7%) 30 (7%) 25 (6%) 55 (7%)
Oedema 20 (5%) 26 (6%) 26 (6%) 20 (5%) 46 (6%)
Other 52 (13%) 50 (12%) 45 (11%) 57 (14%) 102 (12%)
None of the above 186 (45%) 186 (45%) 192 (46%) 180 (43%) 372 (45%)
Not known 79 (19%) 83 (20%) 80 (19%) 83 (20%) 162 (20%)
DCIS associated with tumour
No 186 (45%) 183 (44%) 186 (45%) 183 (44%) 369 (45%)
Yes 110 (27%) 96 (23%) 112 (27%) 94 (23%) 206 (25%)
Not known 117 (28%) 136 (33%) 116 (28%) 137 (33%) 253 (31%)
EC=epirubicin-cyclophosphamide. ER=oestrogen receptor. PR=progesterone receptor. DCIS=ductal carcinoma in situ. *Stratiﬁ cation variables at randomisation. †ER and PR positive was a score of ≥3 on the 
8 point Allred scale. ‡HER2-negative deﬁ ned as immunohistochemistry score of 0–1, or 2, but ﬂ uorescence in-situ hybridisation (FISH) negative; HER2-positive deﬁ ned as immunohistochemistry of ≥3 or ≥2 and 
FISH positive. §Patients could have both inﬂ ammatory disease and advanced disease. ¶Each tumour could have multiple types and characteristics recorded.
Table 1: Patient and tumour characteristics at baseline
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For the primary analysis, we calculated pCR for all 
treatment groups and used univariate logistic 
regression to test the addition of gemcitabine and the 
role of sequencing. We used multivariate logistic 
regression to calculate p values for both the treatment 
and scheduling eﬀ ects after adjustment for prognostic 
factors.
We calculated DFS from the date of randomisation to 
the date of ﬁ rst event (locoregional relapse, distant 
relapse, progression on neoadjuvant chemotherapy, or 
death), or to the date of censoring. We calculated overall 
survival from the date of randomisation to the date of 
death or to the date of each patient’s last clinic visit (for 
women who are not known to have died). We constructed 
Kaplan-Meier curves and compared the main treatment 
eﬀ ect and main scheduling eﬀ ect with log-rank tests. 
We used Cox proportional-hazards models to assess 
and adjust for prognostic factors. When assessing the 
association between pathological response and these 
outcomes, we calculated overall survival and DFS from 
date of surgery.
The Neo-tAnGo protocol stated that the ﬁ rst planned 
interim analysis of DFS and overall survival would 
occur when at least 120 events had occurred or when 
median follow-up was at least 3 years. We report the 
results of this ﬁ rst protocol-stated interim analysis of 
overall survival and DFS.
The methods for dose intensity calculations have 
previously been described.18 We compared course-
delivered dose intensities (CDDI) across treatment groups 
with Wilcoxon rank sum tests and Fisher’s exact tests.
We compared number of patients with severe toxicity 
(CTC grade ≥3, or 2 for alopecia or superﬁ cial thrombo-
phlebitis) during chemotherapy across treatment 
groups.
Analyses were done by Warwick Clinical Trials Unit 
with SAS statistical software (version 9.3).
This study is registered with EudraCT (2004-002356-34), 
ISRCTN (78234870), and ClinicalTrials.gov (NCT00070278).
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding authors (HME 
and LH) had full access to all of the data and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between Jan 18, 2005, and Sept 28, 2007, we recruited 
831 patients at 57 centres; three patients were found to 
be ineligible after randomisation, leaving 828 for 
analysis (ﬁ gure 1; table 1). Protocol violations occurred 
in 27 patients according to the trial management 
committee (ﬁ gure 1). 13 of these violations were due to 
n Component analysis Sequencing analysis
EC and paclitaxel 
(n=404)
EC and paclitaxel-
gemcitabine
(n=408)
p value* EC followed by paclitaxel 
with or without gemcitabine 
(n=406)
Paclitaxel with or without 
gemcitabine followed by EC 
(n=406)
p value*
pCR ·· 70 (17%, 14–21) 71 (17%, 14–21) 0·98 (0·95†) 59 (15%, 11–18) 82 (20%, 16–24) 0·03 (0·02†)
HER2-negative 505 14% (10–19) 16% (12–21) 0·46 13% (9–17) 18% (13–23) 0·03
HER2-positive 187 21% (13–30) 22% (14–32) ·· 17% (10–26) 26% (17–36) ··
ER-negative 269 32% (24–41) 31% (23–40) 0·97 30% (23–39) 33% (25–42) 0·02
ER-positive 543 10% (7–14) 11% (7–15) ·· 7% (4–10) 14% (10–19) ··
Grade 1–2‡ 263 7% (4–13) 6% (3–12) 0·19 7% (3–13) 7% (3–12) 0·10
Grade 3‡ 324 22% (16–29) 30% (23–38) ·· 21% (15–29) 31% (24–38) ··
ER-positive, HER2-negative 348 7% (4–11) 8% (5–14) 0·61 5% (2–9) 10% (6–15) 0·02
ER-positive, HER2-positive 121 17% (9–29) 19% (10–31) ·· 9% (4–19) 28% (17–42) ··
ER-negative, HER2-negative 157 32% (21–43) 32% (22–43) ·· 29% (19–40) 35% (25–47) ··
ER-negative, HER2-positive 66 26% (13–44) 28% (14–47) ·· 32% (17–51) 23% (10–40) ··
ER-positive, HER2-negative (grade 1–2) 147 4% (1–11) 3% (0–10) 0·23 4% (1–11) 3% (0–10) 0·03
ER-positive, HER2-negative (grade 3) 110 12% (5–23) 16% (7–29) ·· 7% (1–18) 18% (10–30) ··
ER-positive, HER2-positive (grade 1–2) 38 10% (1–32) 6% (0–27) ·· 0% (0–17) 17% (4–41) ··
ER-positive, HER2-positive (grade 3) 55 23% (8–45) 30% (16–49) ·· 14% (4–33) 41% (22–61) ··
ER-negative, HER2-positive (grade 1–2) 21 25% (5–57) 11% (0–48) ·· 33% (7–70) 8% (0–38) ··
ER-negative, HER2-positive (grade 3) 30 23% (5–54) 41% (18–67) ·· 38% (15–65) 29% (8–58) ··
ER-negative, HER2-negative (grade 1–2) 21 0% (0–37) 23% (5–54) ·· 10% (0–44) 18% (2–52) ··
ER-negative, HER2-negative (grade 3) 94 31% (18–47) 39% (25–54) ·· 30% (17–45) 40% (26–56) ··
Data are n (%, 95% CI) or % (95% CI), unless otherwise indicated. pCR was deﬁ ned as no invasive disease in breast or axillary lymph nodes. EC=epirubicin-cyclophosphamide. *p value for treatment groups, after 
adjustment for the factor, unless otherwise stated. †Adjusted for the ﬁ ve stratiﬁ cation variables (age, ER status, tumour size, clinical involvement of axillary nodes, and inﬂ ammatory or locally advanced disease). 
‡Tumour grade of each patient’s largest breast tumour at baseline.
Table 2: Rates of pathological complete response (pCR) 
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omission of the ﬁ nal cycle of chemotherapy, with the 
patient proceeding straight to surgery.
Because the Neo-tAnGo protocol did not include 
neoadjuvant trastuzumab, we expected fewer patients with 
HER2-positive disease to enrol as the trial progressed. 
107 patients enrolled in 2005–06 had HER2-positive 
disease (30% of the 357 tested) compared with 84 in 2007 
(24% of the 347 tested; p=0·19).
All patients had surgery (breast and axilla) according to 
local protocols and the details will form the basis of a 
future publication. All patients with ER-positive disease 
(543 [67%] patients were ER-positive) received appropriate 
adjuvant hormonal treatments and 750 patients (91%) 
received radiotherapy treatments according to local 
protocols. 183 (96%) of 191 patients with HER2-positive 
disease received adjuvant trastuzumab.
812 eligible patients had available pathology reports 
from surgery after chemotherapy. 141 (17%) of these 
patients had pCR, which was much the same for patients 
in the epirubicin and cyclophosphamide plus paclitaxel, 
and the epirubicin and cyclophosphamide plus paclitaxel 
and gemcitabine groups (between-group diﬀ erence 
0·07%, 95% CI –5 to 5; table 2). However, signiﬁ cantly 
more patients who received paclitaxel (with or without 
gemcitabine) before epirubicin and cyclophosphamide 
achieved pCR than did those who received epirubicin 
and cyclophosphamide ﬁ rst (between group diﬀ erence 
6%, 0·5 to 11; table 2). In post-hoc analysis, we noted no 
interaction between component and sequence (p=0·86), 
suggesting the eﬀ ects were independent from each 
other. Adjustment by stratiﬁ cation factors did not aﬀ ect 
the results (table 2). Subgroup analysis by HER2 status, 
ER status, or tumour grade did not aﬀ ect the results 
(table 2, appendix).
Median follow-up was 47 months (IQR 37–51). At the 
time of analysis, 167 (20%) of the 828 eligible patients 
had died, 227 (27%) had had locoregional or distant 
relapses, and 236 (29%) had had DFS events. We noted 
no signiﬁ cant diﬀ erence in DFS or overall survival 
between treatment components or treatment sequences 
(ﬁ gure 2). Adjustment for stratiﬁ cation variables did not 
aﬀ ect these ﬁ ndings (ﬁ gure 2).
Full treatment details were available for 819 (99%) of 
828 patients (410 patients in the epirubicin and 
Figure 2: Disease-free survival and overall survival from randomisation
(A) Disease-free survival by treatment component. (B) Disease-free survival by treatment sequence. (C) Overall survival by treatment component. (D) Overall survival by treatment sequence 
EC=epirubicin and cyclophosphamide. HR=hazard ratio. *Adjusted for stratiﬁ cation variables.
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cyclophosphamide and paclitaxel group vs 409 patients in 
the epirubicin and cyclophosphamide, then paclitaxel and 
gemcitabine group; 413 patients in the epirubicin and 
cyclophosphamide followed by paclitaxel with or without 
gemcitabine group vs 406 patients in the paclitaxel with or 
without gemcitabine followed by epirubicin and 
cyclophosphamide group). Seven patients received no 
treatment cycles at all, mainly because of patient choice or 
early relapse. 702 (86%) of the remaining 812 patients 
received eight cycles of chemotherapy; the main reasons 
for not receiving all eight cycles were toxicity (54 [49%] of 
the 110 patients receiving between one and seven cycles), 
disease progression (28 [25%] patients), allergic reaction to 
paclitaxel (15 [14%] patients), poor response to chemotherapy 
(seven [6%] patients), or other reasons (six [5%] patients).
The median CDDI for the 819 patients was 97% (IQR 
91–99%). We noted no diﬀ erences in CDDI between the 
component groups or the sequencing groups (p=0·96 for 
component analysis and p=0·46 for sequencing analysis; 
appendix). 84% of patients received optimum CDDI 
(≥85%). No diﬀ erences between the component groups or 
the sequencing groups were detected (p=0·56 for 
component analysis and p=0·18 for sequencing analysis).
Dose intensities over individual cycles did not notably 
deteriorate for any of the four randomised treatment 
groups (appendix). Moreover, no diﬀ erences of note 
existed between either the taxane-containing and 
anthracycline-containing regimens, or between the four 
randomised treatment groups. More dose reductions for 
the fourth cycle of regimens containing paclitaxel (with 
or without gemcitabine) occurred when it was given 
second compared with prior administration (22% vs 10%, 
respectively; appendix), and similarly for dose delays 
(15% vs 11%, respectively; appendix).
Overall survival from surgery was longer for patients 
attaining pCR than it was for those who did not attain pCR 
(ﬁ gure 3). 12 (9%) of 141 patients with pCR died, as did 147 
(22%) of 671 patients without a pCR. In our analysis of 
DFS, 18 (13%) of 141 patients with pCR relapsed or died 
compared with 206 (31%) of 671 patients who did not 
achieve a pCR (ﬁ gure 3).
GCSF use was reported in 515 (8%) of 6189 cycles 
(appendix); 270 (52%) within taxane-containing cycles. 
179 (22%) of 812 patients received GCSF, which was 
similar across treatment groups (p=0·90 for the 
component analysis and p=0·51 for the sequencing 
analysis; appendix). Incidence of severe toxicities 
(grade 3–4) by cycle and patient are shown in table 3 and 
table 4 and mild toxicities (grade 1–2) are reported in the 
appendix. Adverse events were as expected. Grade 
3 toxicities included neutropenia, muscle and joint pain, 
infection, neuropathy, transaminitis, fatigue, nausea and 
vomiting, rash, and acute hypersensitivity (table 3). Grade 
4 toxicities included neutropenia and infection (table 4). 
Accelerated paclitaxel (with or without gemcitabine) was 
both tolerable and deliverable.
Only two patients died during chemotherapy. One 
patient in the paclitaxel followed by epirubicin and cyclo-
phosphamide group died of neutropenic sepsis and 
pneumonia 11 days after their third dose of paclitaxel. 
One patient in the epirubicin and cyclo phosphamide 
followed by paclitaxel group died of venous 
thromboembolism 2 days after the third dose of 
epirubicin and cyclo phosphamide. Another two patients 
died within 3 months of completion of chemotherapy but 
causes were unrelated to treatment. One patient in the 
epirubicin and cyclophosphamide followed by paclitaxel 
group received only ﬁ ve cycles of chemotherapy because 
of fatigue and anaphylaxis and then died 12 weeks later of 
respiratory failure (distant recurrence with bilateral 
pleural eﬀ usion and extensive alveolar shadowing). One 
patient in the paclitaxel and gemcitabine followed by 
epirubicin and cyclo phosphamide group completed only 
seven cycles of chemotherapy because of disease 
progression and died 5 weeks later from recurrence of 
leptomeningeal breast cancer.
Figure 3: Disease-free survival and overall survival from surgery by pathological complete response
(A) Disease-free survival. (B) Overall survival. pCR=pathological complete response. HR=hazard ratio. *Adjusted for 
stratiﬁ cation variables.
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Discussion
In our study, provision of a taxane before standard 
anthracycline chemotherapy was associated with a 
signiﬁ cant improvement in pCR, from 15% to 20%, 
compared with a standard anthracycline-ﬁ rst sequence 
(p=0·03; panel). Addition of gemcitabine did not provide 
signiﬁ cant beneﬁ t overall. Achievement of a pCR was 
correlated with signiﬁ cant improvement in DFS 
(p<0·0001) and overall survival (p=0·0007). These 
ﬁ ndings conﬁ rm the beneﬁ t of taxane-ﬁ rst sequencing 
that was noted in a large retrospective non-randomised 
study from the MD Anderson Cancer Center, TX, USA,19 
which reported data from 1414 patients treated with 
neoadjuvant chemotherapy and 1596 patients treated with 
adjuvant chemotherapy between 1994 and 2009. 88% of 
these patients received paclitaxel-ﬁ rst sequencing and 
showed increased pCR (20·9% vs 12·4%), and fewer 
relapses occurred in the neoadjuvant patient group. 
EC followed by paclitaxel Paclitaxel followed by EC EC followed by paclitaxel-gemcitabine Paclitaxel-gemcitabine followed by EC
EC Paclitaxel Paclitaxel EC EC Paclitaxel-
gemcitabine
Paclitaxel-
gemcitabine
EC
Cycles Patients Cycles Patients Cycles Patients Cycles Patients Cycles Patients Cycles Patients Cycles Patients Cycles Patients
Neutropenia 17 14 3 3 7 5 17 15 31 21 8 7 7 7 25 19
Infection ·· ·· 1 1 1 1 ·· ·· ·· ·· ·· ·· ·· ·· 1 1
Fatigue 2 1 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 1 1 1 1
Muscle or joint pain ·· ·· 1 1 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
Vomiting ·· ·· ·· ·· ·· ·· ·· ·· 3 2 ·· ·· 1 1 ·· ··
Neurosensory 1 1 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
Rash ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 1 1 ·· ·· ·· ··
Diarrhoea ·· ·· ·· ·· ·· ·· 1 1 ·· ·· ·· ·· ·· ·· ·· ··
Constipation ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 1 1 ·· ··
Dyspnoea ·· ·· ·· ·· ·· ·· 1 1 ·· ·· ·· ·· ·· ·· ·· ··
Alopecia, superﬁ cial thrombophlebitis, and cough do not have a common terminology criteria for adverse events grade of 4. EC=epirubicin-cyclophosphamide. ··=no reported toxic eﬀ ects of this grade.
Table 4: Reported grade 4 severe toxic eﬀ ects
EC followed by paclitaxel Paclitaxel followed by EC EC followed by paclitaxel-gemcitabine Paclitaxel-gemcitabine followed by EC
EC Paclitaxel Paclitaxel EC EC Paclitaxel-
gemcitabine
Paclitaxel-
gemcitabine
EC
Cycles Patients Cycles Patients Cycles Patients Cycles Patients Cycles Patients Cycles Patients Cycles Patients Cycles Patients
Neutropenia 35 28 28 21 15 13 48 36 40 29 27 22 11 10 42 31
Infection 15 14 4 3 4 3 11 10 12 11 7 7 9 8 14 13
Fatigue 8 6 6 4 8 5 5 4 2 2 7 7 11 9 10 8
Muscle or joint pain ·· ·· 10 10 10 8 ·· ·· ·· ·· 19 15 10 6 4 3
Vomiting 13 11 1 1 ·· ·· 10 7 10 9 ·· ·· ·· ·· 11 9
Nausea 7 6 1 1 ·· ·· 14 10 14 12 1 1 ·· ·· 7 7
Neurosensory ·· ·· 11 10 7 7 1 1 ·· ·· 10 9 8 7 2 2
Transaminitis ·· ·· ·· ·· 2 2 1 1 1 1 17 9 15 10 1 1
Rash ·· ·· 3 3 3 3 ·· ·· ·· ·· 1 1 14 13 ·· ··
Fever 6 5 1 1 ·· ·· 2 2 2 2 ·· ·· 2 2 5 5
Acute hypersensitivity ·· ·· 2 2 1 1 ·· ·· ·· ·· 3 3 10 10 ·· ··
Diarrhoea ·· ·· ·· ·· ·· ·· 1 1 1 1 2 2 3 3 4 4
Constipation ·· ·· ·· ·· 5 2 ·· ·· 1 1 1 1 3 2 ·· ··
Dyspneoa 1 1 1 1 ·· ·· ·· ·· ·· ·· ·· ·· 2 2 2 2
Anaemia 2 2 1 1 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
Thrombocytopenia ·· ·· ·· ·· ·· ·· 3 2 ·· ·· ·· ·· ·· ·· ·· ··
Cough ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 2 2
Deep vein thrombosis ·· ·· ·· ·· ·· ·· ·· ·· 1 1 ·· ·· 1 1 ·· ··
Stomatitis ·· ·· ·· ·· 1 1 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
Alopecia and superﬁ cial thrombophlebitis do not have a common terminology criteria for adverse events (CTCAE) grade of 3. EC=epirubicin-cyclophosphamide. ··=no reported toxic eﬀ ects of this grade.
Table 3: Reported grade 3 severe toxic eﬀ ects
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314 patients have been included in small randomised 
phase 2 adjuvant trials20–24 and 276 patients have been 
included in neoadjuvant trials25–28 addressing taxane and 
anthracycline sequencing. Some of these studies report 
more dose reductions of taxane when anthracyclines are 
given ﬁ rst,21–23,25 and one randomised neoadjuvant study 
showed a non-signiﬁ cant increase in incidence of pCR for 
taxane-ﬁ rst sequencing.27 Indirect evidence from neo-
adjuvant randomised studies for taxane-ﬁ rst sequencing 
comes from EORTC 10994,28 which compared 
ﬂ uorouracil, epirubicin, and cyclophosphamide with 
docetaxel followed by epirubicin and docetaxel. The HR 
for DFS beneﬁ t was 0·85 (stratiﬁ ed log-rank p=0·035). 
Neo-tAnGo conﬁ rms the improvement in pCR with 
taxane-ﬁ rst sequencing suggested by these previous 
studies. However, the Neo-tAnGo analysis showed no 
sequence-speciﬁ c diﬀ erence in CDDI to explain this 
taxane-ﬁ rst sequence result.
Preclinical and clinical studies have suggested 
mechanisms to explain the beneﬁ t of early receipt of 
taxanes. Cross-resistance has been shown to emerge 
dependent on sequence. An in-vitro study of MCF-7 cells29 
showed that when these cells were made resistant to 
doxorubicin, cross-resistance to paclitaxel increased 
4700 times. However when MCF7 cells were made 
resistant to paclitaxel, the cross-resistance for doxorubicin 
was only four times higher. Pachmann and colleagues30 
describe release of breast cancer circulating tumour cells 
(CTCs) during paclitaxel treatment and a decrease in 
CTCs during anthracyclines. The study30 suggests that 
increased long-term beneﬁ t might be achieved by taxane-
ﬁ rst sequencing. Taghian and colleagues26 drew attention 
to increases in interstitial ﬂ uid pressure and improved 
oxygenation within breast tumours after neoadjuvant 
paclitaxel, which might allow increased concentrations of 
anthracyclines to accumulate within tumour tissue when 
given afterwards. In addition, preclinical data show that 
in breast cancer cells with heat shock protein 
27 overexpression, a paclitaxel then doxorubicin sequence 
is more eﬀ ective at cell killing than the more standard 
doxorubicin then paclitaxel sequence.31
Taxane-ﬁ rst sequences allow early treatment with 
concomitant trastuzumab and bevacizumab, which 
might provide additional therapeutic advantage, shown 
for trastuzumab in the FinHer study.32 Both the 
NSABP-B4015 and ARTemis33 trials of bevacizumab have 
adopted taxane-ﬁ rst sequencing for this reason. Because 
all patients receive both the taxane and anthracycline 
components, taxane-ﬁ rst sequencing could be considered 
in all similar block-sequential adjuvant and neoadjuvant 
protocols.
Neo-tAnGo conﬁ rms the result of tAnGo11 and shows 
no signiﬁ cant beneﬁ t from addition of gemcitabine to a 
combination that already contains anthracycline, 
cyclophosphamide, and paclitaxel. However, gemcitabine 
has shown promising results in patients with metastatic 
disease when added to paclitaxel in the ﬁ rst-line relapse 
setting.13 Much the same results have already been 
reported in the adjuvant NSABP-B38,14 and neoadjuvant 
NSABP-B4015 studies. NSABP-B38 showed no beneﬁ t for 
gemcitabine with paclitaxel used in the same dose and 
schedule as in NeotAnGo. NSABP-B40 had a complex 
design, but for the purposes of discussion here, 
addressed the addition of gemcitabine to docetaxel. 
Gemcitabine was given at 666 mg/m² per week 
(compared with 1000 mg/m² per week in NeotAnGo and 
NSABP-B38) and docetaxel doses were reduced to 
75 mg/m² , and showed no beneﬁ t in terms of pCR. In 
Neo-tAnGo, we noted a non-signiﬁ cant increase in pCR 
after the addition of gemcitabine in patients with high-
grade disease (table 2).
Paclitaxel was delivered every 14 days at 175 mg/m² (with 
or without gemcitabine 2000 mg/m²). This dose-dense 
protocol was delivered without any reported delays in 82% 
of paclitaxel-containing cycles and only 8% of cycles 
required growth factor support to maintain dose intensity. 
This schedule allowed a 50% increase in dose density 
compared with dosing once every 21 days and also reduced 
the total time of chemotherapy. This strategy provides a 
cost-eﬀ ective and well-tolerated way to achieve dose 
intensiﬁ cation of paclitaxel. The use of neoadjuvant or 
adjuvant weekly paclitaxel is now often used as standard at 
80 mg/m² per week and therefore the taxane-ﬁ rst 
sequencing beneﬁ t seen in Neo-tAnGo with paclitaxel at 
87·5 mg/m² per week, is close to standard practice across 
the world.
Whether pCR in neoadjuvant trials can be a surrogate 
endpoint for DFS and overall survival has been debated. 
von Minckwitz and colleagues’ meta-analysis34 of 
6377 patients in the German Breast Group and ABOBSG 
neoadjuvant chemotherapy trials showed that the 
prognostic value of not achieving a pCR is most 
dependent on the molecular subtype of the original 
Panel: Research in context
Systematic review
We searched PubMed for listed articles on neoadjuvant chemotherapy from 1980 onwards. 
In addition all major international early breast cancer trials groups were contacted to discuss 
our proposed design of epirubicin and cyclophosphamide, and dose-dense paclitaxel with 
or without gemcitabine. The NSABP-B38 adjuvant trial had a similar experimental arm with 
dose-dense doxorubicin and cyclophosphamide, and dose-dense paclitaxel (175 mg/m² 
every 2 weeks) with or without gemcitabine (2000 mg/m² every 2 weeks). This trial was 
published in 2013,14 and showed no beneﬁ t to the addition of gemcitabine. The 
NSABP-B40 neoadjuvant trials added gemcitabine or capecitabine and at publication15 in 
2012 showed no beneﬁ t. Neo-tAnGo was unique in also addressing the question of 
paclitaxel-ﬁ rst versus standard anthracycline-ﬁ rst sequencing. In addition, Neo-tAnGo had 
a complementary adjuvant trial (tAnGo) which also addressed the addition of gemcitabine.
Interpretation
Neo-tAnGo conﬁ rms the NSABP-B38,14 NSABP-B40,15 and tAnGo11 results, which show 
no beneﬁ t from the addition of gemcitabine to anthracycline and taxane-based 
chemotherapy treatments for early breast cancer. Neo-tAnGo shows a signiﬁ cant beneﬁ t 
from taxane-ﬁ rst sequencing, and is the largest randomised trial to conﬁ rm this eﬀ ect.
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tumour. Patients with luminal A tumours and a lower 
pCR nevertheless have a better prognosis than do other 
subgroups in terms of DFS and overall survival. 
By comparison with overall pCR reported in the von 
Minckwitz meta-analysis,34 pCR in Neo-tAnGo was lower 
in all groups. For luminal A subtype,35 a meta-analysis 
included 46% of patients in this category with pCR of 
8·9%, whereas Neo-tAnGo had 29% luminal A patients 
with pCR of 3·5%. In addition, 662 (50%) of 1327 patients 
with HER2-positive disease in the meta-analysis received 
neoadjuvant trastuzumab, whereas none of the 
187 patients with HER2-positive disease in Neo-tAnGo 
did. Neoadjuvant trastuzumab increased the pCR by an 
absolute of 15% in these 662 patients in the meta-
analysis. However in the triple-negative subgroup, pCR 
rates are much the same between studies. The meta-
analysis shows pCR of 35·8% in 911 patients, although in 
a recent trial (GEPAR Quinto),36 663 patients with triple-
negative breast cancer had a pCR of 27·9%, increasing to 
39·3% after the addition of bevacizumab to 
chemotherapy. The pCR for 94 such patients in Neo-
tAnGo was 39% with the addition of gemcitabine and 
40% with taxane-ﬁ rst sequence.
In the Z1040-Alliance neoadjuvant study,37 280 patients 
with HER2-positive breast cancer were randomly 
allocated to receive standard ﬂ uorouracil, epirubicin, and 
cyclophosphamide followed by weekly paclitaxel with 
trastuzumab (pCR in the breast 56·5%), and a taxane-
ﬁ rst sequence with concurrent weekly trastuzumab 
throughout (pCR in the breast 54·2%). However in Neo-
tAnGo, 187 patients with HER2-positive disease had a 
pCR for taxane-ﬁ rst sequence of 26% compared with 17% 
for standard sequence (p=0·03; table 2). Notably, in Neo-
tAnGo, in 121 ER-positive, HER2-positive women, pCR 
was 28% for taxane-ﬁ rst sequencing and 9% for 
anthracycline-ﬁ rst sequencing, and in 66 ER-negative, 
HER2-positive women pCR was 23% for taxane-ﬁ rst 
sequencing and 32% for anthracycline-ﬁ rst sequencing. 
The Neo-tAnGo subgroups are too small to draw 
conclusions and the results can only be hypothesis-
generating. However, the diﬀ erences between the Neo-
tAnGo results and Z1040 could be explained by the 
absence of neoadjuvant trastuzumab in Neo-tAnGo.
A recent meta-analysis38 by the US Food and Drug 
Administration (FDA) conﬁ rms the strong correlation 
between pCR and DFS and overall survival in patients 
achieving a pCR, and this association was conﬁ rmed in 
Neo-tAnGo. However, the association is complex. 
The FDA proposed that pCR in neoadjuvant trials in 
highly proliferative breast cancers could now contribute 
to accelerated drug approval in these types of early breast 
cancer.39 This proposal is a landmark in neoadjuvant 
chemotherapy trials for highly proliferative breast cancer, 
and will facilitate more rapid introduction of new agents 
for this subtype. Randomised neoadjuvant trials of 
chemotherapy in combination with target-directed novel 
agents will be able to focus on high proliferation 
molecular subtypes (ER-negative, HER2-positive, high 
grade, and patients with germline BRCA mutations) in 
which the association between pCR and DFS and overall 
survival is expected to be correlated. 
However, the FDA meta-analysis also indicates 
subgroups of breast cancer with lower proliferative 
potential (ie, ER-positive, HER2-negative, low and 
intermediate grade) that have a better prognosis 
independent of pCR. In these groups, the response to 
chemotherapy is poor and pCR is low but the long-term 
outcome is good, and survival is inﬂ uenced more by 
subsequent adjuvant hormonal treatment. In Neo-
tAnGo, patients from all the diﬀ erent prognostic groups 
were included, and therefore the proﬁ le of the trial 
population will weaken the correlation between pCR and 
long-term outcomes for the group as a whole. In future, 
neoadjuvant clinical trials will probably include speciﬁ c 
prognostic groups. For patients with a previously known 
poor prognosis, who have high pCR incidence, a robust 
and reliable correlation will probably emerge between 
pCR and longer-term outcome.
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